1st Edition
Need-to-Know NAFLD The Complete Guide to Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the obesity and metabolic syndrome epidemics, which this up-to-date book deals with comprehensively. The contents outline disease mechanisms, diagnostic tests, management, varying manifestations, and special populations. It covers the mechanistic pathways that contribute to NAFLD development, including the role of genetic variants and the gut microbiome. It elaborates on noninvasive diagnostic tests to screen for NAFLD, determine its severity, and monitor response to lifestyle intervention and pharmacologic treatment. This book helps clinicians diagnose and treat this common and potentially deadly disease.
Key Features:
- Reviews current drugs in development and provides practical advice to clinicians on the diagnosis and management of fatty liver.
- Proves attractive to primary care providers who are on the front line of managing patients with NAFLD, to gastroenterologists and hepatologists who would benefit from updated data on how to risk-stratify patients and identify those who will be eligible for pharmacologic treatment, and other specialists such as cardiologists, endocrinologists, and nephrologists who will find this book to be a useful reference on the extrahepatic manifestations of NAFLD.
- Focuses on extrahepatic manifestations and new insights on the mechanistic drivers of the disease.
Preface – Naim Alkhouri and Stephen A Harrison
Section 1. Mechanisms of NAFLD Development
1.Historical Perspectives and Clinical Presentation - Imad Asaad, Naim Alkouri
2.Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis - Linda Henry, Zobair M Younossi
3.Genetics of NAFLD - Luca Valenti, Cristiana Bianco
4.Mechanisms of hepatocyte injury and inflammation in NAFLD - Gopanandan Parthasarathy, Harmeet Malhi
5.The role of the microbiome - Carlos J Pirola and Silvia Sookoian
Section 2. Diagnostic Tests
6.Simple Algorithms in Primary Care - Xixi Xu, and Michelle T. Long
7.Ultrasound based techniques in NAFLD - Vikas Taneja, Nezam H Afdhal, and Michelle J Lai
8.MRI-based technologies - Victor de Lédinghen
9.Artificial intelligence in NAFLD diagnosis - Joseph C. Ahn, and Samer Gawrieh
Section 3. Management
10.Dietary interventions - Monica Tincopa
11.Weight Loss Medications - Mohammad Qasim Khan, Manhal Izzy, Kymberly D. Watt
12.De novo lipogenesis inhibitors - Brent A. Neuschwander-Tetri
13.Targeting bile acids (FXRs and FGF19) - Daniel Garrido, Rukaiya Bashir Hamidu, Dina Halegoua-DeMarzio
14.PPAR agonists - Sven MA Francque
15.Anti-inflammatory drugs: Metabolic inflammation in NASH as a therapeutic target - Angelo Armandi, Jörn M. Schattenberg
16.Practical Aspects of Pharmacologic Management - Naim Alkhouri and Stephen A. Harrison
Section 4. Extrahepatic Manifestations
17.Endocrinology: Diabetes and other endocrinopathies - Scott Isaacs, Julio Leey
18.Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease - Dania Brigham and Shikha S. Sundaram
19.Extrahepatic Gastrointestinal Manifestations of Non-alcoholic Fatty Liver Disease - Rinjal Brahmbhatt, Mousab Tabbaa
20.Extrahepatic and Hepatic cancers - Maryam Ibrahim, Tracey G. Simon
Section 5. NAFLD in special populations
21.NAFLD in Children: Unique Aspects and Controversies - Samar H Ibrahim, Rohit Kohli
22.NAFLD in HIV patients - Giada Sebastiani
23.NAFLD in Liver Transplant Recipients - Liyun Yuan and Norah Terrault
24.NAFLD in lean individuals - Donghee Kim and Vincent Wai-Sun Wong
Biography
Naim Alkhouri, MD, is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, Arizona. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, Texas. Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, Ohio, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute. Dr. Alkhouri is a key opinion leader in the field of NASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global NASH trials and a member of the AASLD NASH Special Interest Group (NASH SIG).
Dr. Alkhouri has been published in more than 200 publications, including the New England Journal of Medicine, Lancet, JAMA, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease.
Stephen A. Harrison, MD, is the Founder and Chairman of Pinnacle Clinical Research and Co-Founder and Chairman of Summit Clinical Research, LLC in San Antonio, Texas. He is board-certified in Internal Medicine and Gastroenterology. Dr. Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center before completing a 4-year advanced liver disease fellowship at Saint Louis University. Dr. Harrison served as a Professor of Medicine at the Uniformed Services University of the Health Sciences and is currently a Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford.
Dr. Harrison served as a Colonel in the United States Army. Retiring in 2016, he concluded 20 years of dedicated service to his country. During his army tenure, he served as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium and Gastroenterology Consultant to the Army Surgeon General. He is a past Associate Editor for Hepatology and Alimentary Pharmacology & Therapeutics journals. He is internationally known for studies in nonalcoholic fatty liver disease (NAFLD) with more than 300 peer-reviewed publications in top-tier journals including the New England Journal of Medicine, Nature Medicine, Lancet, JAMA, Gastroenterology, Journal of Hepatology and Hepatology. He has an H-Index of 93.
